文献速递妇产影像腹部介入US

甲氨蝶呤在妇产科实践中的应用:放射科医生需要了解的内容

Use of Methotrexate in Gynecologic and Obstetric Practice: What the Radiologist Needs to Know.
PubMed 文献 · Radiographics · 2021-01-01

本文综述甲氨蝶呤(MTX)治疗滋养细胞组织疾病(异位妊娠和妊娠滋养细胞疾病)的机制、给药途径和方案,重点讨论超声在诊断、评估MTX适用标准及识别治疗后预期与并发症征象中的作用,以指导患者管理并避免不必要的有创操作。

要点

  • 超声是评估异位妊娠类型、MTX适用标准及治疗后变化的核心工具。
  • MTX治疗后异位妊娠的回声、形态、大小、血供及盆腔积血可发生预期变化。
  • 识别妊娠进展或破裂、严重出血、败血性流产及动静脉交通等并发症的超声征象至关重要。

核心结论

  • 放射科医生应熟悉MTX治疗滋养细胞组织疾病的机制、方案及超声在评估适用标准、预期治疗后改变和识别失败/并发症征象中的作用。

研究设计与样本

  • 本文为叙述性综述,基于妇产科与放射学文献及作者经验,总结MTX在异位妊娠和妊娠滋养细胞疾病中的应用及超声作用。

关键影像表现/征象

  • MTX治疗后异位妊娠可出现回声和形态变化、大小波动、血供改变及妊娠囊内容物变化。
  • 盆腔积血程度可用于评估病情及治疗效果。
  • 输卵管或子宫破裂、严重出血、败血性流产及动静脉交通形成等并发症具有相应超声征象。

诊断标准与关键数值

  • 异位妊娠类型不同,MTX给药途径和剂量可能不同。
  • 超声用于评估MTX使用适用标准,并识别治疗成功与失败的影像学表现。

临床应用与阅片要点

  • 阅片时应熟悉MTX治疗后异位妊娠的回声、形态、大小、血供及妊娠囊内容的预期变化,避免误判为治疗失败。
  • 识别提示妊娠进展或并发症(如破裂、严重出血、败血性流产、动静脉交通)的超声征象,以便及时手术干预。
  • 超声评估MTX适用标准时需明确异位妊娠类型,因不同类型给药途径和剂量可能不同。

局限性

  • 本文为综述,未报告原始研究样本量、敏感度、特异度等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Methotrexate (MTX) is the primary pharmaceutical agent that is used for management of disorders arising from trophoblastic tissue. Its widespread international use is mostly attributable to its noninvasive, safe, and effective characteristics as a treatment option for ectopic pregnancy (EP) and gestational trophoblastic disease (GTD), with the large added benefit of fertility preservation. Although the effects of MTX usage are well documented in the gynecologic and obstetric literature, there is a scarcity of radiologic literature on the subject. Depending on the type of EP, the route of MTX administration and dosage may vary. US plays an essential role in the diagnosis and differentiation of various types of EPs, pregnancy-related complications, and complications related to MTX therapy, as well as the assessment of eligibility criteria for MTX usage. A knowledge of expected imaging findings following MTX treatment, including variability in echogenicity and shape of the EP, size fluctuations, changes in vascularity and gestational sac content, and the extent of hemoperitoneum, is essential for appropriate patient management and avoidance of unnecessary invasive procedures. A recognition of sonographic findings associated with pregnancy progression and complications such as tubal or uterine rupture, severe hemorrhage, septic abortion, and development of arteriovenous communications ensures prompt patient surgical management. The authors discuss the use of MTX in the treatment of disorders arising from trophoblastic tissue (namely EP and GTD), its mechanism of action, its route of administration, and various treatment regimens. The authors also provide a focused discussion of the role of US in the detection and diagnosis of EP and GTD, the assessment of the eligibility criteria for MTX use, and the identification of the sonographic findings seen following MTX treatment, with specific emphasis on imaging findings associated with MTX treatment success and failure. Online supplemental material is available for this article. ©RSNA, 2021.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Revzin MV, Pellerito JS, Moshiri M, et al. Use of Methotrexate in Gynecologic and Obstetric Practice: What the Radiologist Needs to Know. Radiographics. 2021. PMID: 34597234. doi:10.1148/rg.2021210038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。